Ornique (Ethinylestradiol, Etonogestrel)

The ethinylestradiol component mimics natural estrogen, while etonogestrel acts as a progestogen. Together they inhibit the hypothalamic‑pituitary‑gonadal axis, reducing luteinizing hormone and follicle‑stimulating hormone release, which prevents ovulation. The progestogen also thickens cervical mucus and modifies the uterine lining to impede fertilisation and implantation.

The dosing regimen for Ornique is determined by the prescribing healthcare professional. Typically, a vaginal ring is inserted and left in place for a specified period (often three weeks) followed by a ring‑free interval, but the exact schedule must be individualized and confirmed by the prescriber.

Ornique is classified as Pregnancy Category X, meaning it must not be used during pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as hormonal exposure may affect milk production and infant development. Women should discontinue use if they become pregnant.

To order Ornique, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature control), and import documentation.

Ornique delivers hormones via a vaginal ring, offering continuous low‑dose exposure and eliminating daily oral dosing. Compared with combined oral contraceptives, the ring may provide more stable hormone levels, reduced gastrointestinal side effects, and improved adherence, though both share similar efficacy and safety profiles when used correctly.

Ornique should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture, direct sunlight, and excessive heat. Maintaining these conditions helps preserve the integrity of the hormone‑release system throughout its shelf life.

Ornique is a flexible vaginal ring that is inserted into the vagina by the user or a healthcare professional. The ring remains in place for the prescribed duration (commonly three weeks) and is then removed for a ring‑free interval, after which a new ring is inserted to continue contraception.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, hypertension, severe allergic reactions, and rare hepatic tumors. Women with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should avoid using Ornique.

Ornique is contraindicated in women who are pregnant, have known or suspected estrogen‑dependent tumors, have active or past thromboembolic disease, have uncontrolled hypertension, have severe liver disease, or are smokers aged 35 years or older. It should also be avoided in individuals with known hypersensitivity to any component of the ring.